Related Experiment Videos
Cyclo-oxygenase-2 -765G > C promoter variants are associated with lower carotid plaque echogenicity in Japanese
Shigetaka Furukado1, Manabu Sakaguchi, Hiroshi Yamagami
1Department of Neurology, Stroke Division, Osaka University Graduate School of Medicine, Osaka, Japan.
Background And Purpose:
Recent studies revealed that inflammation contributes to plaque instability. Cyclo-oxygenase (COX)-2 is one of the key enzymes in plaque inflammation. We examined the relation between a polymorphism in the COX-2 gene and carotid plaque echogenicity in patients with high risk of cerebrovascular disease to evaluate the involvement of COX-2 in plaque instability.
Methods:
The study comprised 469 individuals with carotid atherosclerotic plaques. We quantified the echogenicity of the largest plaque in each participant by integrated backscatter analysis. The -765G > C variant of the COX-2 gene was genotyped by restriction enzyme fragment length polymorphism analysis. Urinary 6-keto prostaglandin F(1)(alpha) levels and flow-mediated dilation were measured in 25 participants from the -765GC genotype group and 25 matched participants from the -765GG genotype group.
Results:
The carotid plaque echogenicity in the variant genotype group (n = 44) was lower than that in the -765GG genotype group (n = 425, p = 0.017). The association remained significant when we controlled for atherosclerotic risk factors, plaque thickness and serum levels of interleukin-6 (p = 0.027). The level of urinary 6-keto prostaglandin F(1)(alpha) and flow-mediated dilation in the variant genotype group was significantly lower than that in the -765GG genotype group.
Conclusions:
The -765G > C variant of COX-2 was associated with reduced carotid plaque echogenicity in Japanese. Diminished COX-2 activity in the endothelium may contribute to plaque instability.
Related Concept Videos
Cell Specific Gene Expression
Coronary Artery Disease II: Pathophysiology
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes